up 269-6 has been researched along with cyclic gmp in 1 studies
Studies (up 269-6) | Trials (up 269-6) | Recent Studies (post-2010) (up 269-6) | Studies (cyclic gmp) | Trials (cyclic gmp) | Recent Studies (post-2010) (cyclic gmp) |
---|---|---|---|---|---|
15 | 4 | 0 | 22,346 | 333 | 4,062 |
Protein | Taxonomy | up 269-6 (IC50) | cyclic gmp (IC50) |
---|---|---|---|
Phosphodiesterase | Bos taurus (cattle) | 0.1 | |
cGMP-inhibited 3',5'-cyclic phosphodiesterase B | Homo sapiens (human) | 2.4 | |
cGMP-inhibited 3',5'-cyclic phosphodiesterase A | Homo sapiens (human) | 2.4 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Jugdutt, BI; Menon, V; Xu, Y | 1 |
1 other study(ies) available for up 269-6 and cyclic gmp
Article | Year |
---|---|
Cardioprotection after angiotensin II type 1 blockade involves angiotensin II type 2 receptor expression and activation of protein kinase C-epsilon in acutely reperfused myocardial infarction in the dog. Effect of UP269-6 and losartan on AT1 and AT2-recep
Topics: Angiotensin Receptor Antagonists; Animals; Blood Volume; Calcium Channels; Cardiotonic Agents; Cyclic GMP; Dogs; Enzyme Activation; Female; Hemodynamics; Inositol 1,4,5-Trisphosphate Receptors; Isoenzymes; Losartan; Male; Myocardial Infarction; Myocardial Reperfusion; Myocardium; Protein Kinase C; Protein Kinase C-epsilon; Pyrimidines; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Tetrazoles; Time Factors; Ventricular Function, Left | 2000 |